CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 168 filers reported holding CLOVIS ONCOLOGY INC in Q2 2021. The put-call ratio across all filers is 1.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $851,000 | -21.7% | 715,398 | +18.5% | 0.00% | – |
Q2 2022 | $1,087,000 | -79.5% | 603,898 | -76.9% | 0.00% | – |
Q1 2022 | $5,291,000 | -87.9% | 2,619,477 | -83.7% | 0.00% | -100.0% |
Q4 2021 | $43,670,000 | -33.3% | 16,114,542 | +9.8% | 0.00% | -33.3% |
Q3 2021 | $65,449,000 | +13.8% | 14,674,754 | +48.0% | 0.00% | 0.0% |
Q2 2021 | $57,516,000 | -17.2% | 9,916,565 | +0.2% | 0.00% | -25.0% |
Q1 2021 | $69,448,000 | -0.5% | 9,892,877 | -31.9% | 0.00% | 0.0% |
Q4 2020 | $69,772,000 | +24.1% | 14,535,872 | +50.7% | 0.00% | 0.0% |
Q3 2020 | $56,240,000 | -9.8% | 9,646,730 | +4.4% | 0.00% | -20.0% |
Q2 2020 | $62,361,000 | +167.2% | 9,238,731 | +151.7% | 0.01% | +150.0% |
Q1 2020 | $23,343,000 | -38.8% | 3,670,251 | +0.2% | 0.00% | -33.3% |
Q4 2019 | $38,171,000 | +880.0% | 3,661,449 | +269.5% | 0.00% | – |
Q3 2019 | $3,895,000 | -95.1% | 991,018 | -81.4% | 0.00% | -100.0% |
Q2 2019 | $79,311,000 | -6.1% | 5,333,649 | +56.8% | 0.01% | -14.3% |
Q1 2019 | $84,449,000 | +38.5% | 3,402,443 | +0.2% | 0.01% | +16.7% |
Q4 2018 | $60,985,000 | -32.1% | 3,395,589 | +11.0% | 0.01% | -14.3% |
Q3 2018 | $89,826,000 | -20.1% | 3,058,360 | +23.7% | 0.01% | -22.2% |
Q2 2018 | $112,458,000 | +2.8% | 2,473,176 | +19.3% | 0.01% | 0.0% |
Q1 2018 | $109,432,000 | -14.5% | 2,072,575 | +10.1% | 0.01% | -10.0% |
Q4 2017 | $127,964,000 | -21.8% | 1,881,811 | -5.3% | 0.01% | -28.6% |
Q3 2017 | $163,677,000 | -10.1% | 1,986,425 | +2.2% | 0.01% | -12.5% |
Q2 2017 | $181,966,000 | +53.4% | 1,943,480 | +4.3% | 0.02% | +45.5% |
Q1 2017 | $118,638,000 | +24.7% | 1,863,309 | -13.0% | 0.01% | +22.2% |
Q4 2016 | $95,131,000 | +138.7% | 2,141,663 | +93.7% | 0.01% | +125.0% |
Q3 2016 | $39,862,000 | +77.7% | 1,105,746 | -32.4% | 0.00% | +100.0% |
Q2 2016 | $22,436,000 | -35.0% | 1,635,355 | -9.0% | 0.00% | -50.0% |
Q1 2016 | $34,525,000 | -33.5% | 1,797,874 | +21.2% | 0.00% | -33.3% |
Q4 2015 | $51,948,000 | -22.8% | 1,483,981 | +102.9% | 0.01% | -25.0% |
Q3 2015 | $67,263,000 | +8.5% | 731,429 | +3.7% | 0.01% | +14.3% |
Q2 2015 | $62,004,000 | +23.1% | 705,543 | +4.0% | 0.01% | +40.0% |
Q1 2015 | $50,370,000 | +29.8% | 678,586 | -2.1% | 0.01% | +25.0% |
Q4 2014 | $38,811,000 | +20.9% | 693,094 | -2.1% | 0.00% | +33.3% |
Q3 2014 | $32,108,000 | +15.3% | 707,769 | +5.2% | 0.00% | 0.0% |
Q2 2014 | $27,852,000 | -24.6% | 672,645 | +26.1% | 0.00% | -25.0% |
Q1 2014 | $36,948,000 | -1.6% | 533,333 | -31.5% | 0.00% | +100.0% |
Q4 2013 | $37,546,000 | +10.1% | 778,109 | +38.6% | 0.00% | -50.0% |
Q3 2013 | $34,117,000 | +39.3% | 561,300 | +53.5% | 0.00% | +33.3% |
Q2 2013 | $24,489,000 | – | 365,633 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |